Before dawn, a line gathered outside an Ohio suburban pharmacy. As if willing it to change, a mother wearing yoga pants kept checking her phone and refreshing the prescription tracker app.
The pharmacist inside discreetly reiterated that the shipment had not yet arrived. Birmingham, Manchester, and London have all seen similar scenes. The tension in those conversations is difficult to ignore.
Once a regular prescription for millions of people, ADHD medication has evolved into something completely different: limited, contentious, and politicized.
A portion of the story is revealed by the numbers. Over the past ten years, prescriptions for stimulant drugs like methylphenidate and Adderall have increased significantly in both the US and the UK.
Prescriptions for ADHD have increased annually in England alone, with a particularly sharp increase among adults and women over 25.
Adult use of electronic health records, which was previously uncommon, is now increasing, according to researchers monitoring these records throughout Europe. It seems as though a long-misunderstood condition is finally being acknowledged by society. However, the pendulum might also be swinging too much.
| Category | Details |
|---|---|
| Key Institution (US) | National Institutes of Health |
| Key Authority (US) | Drug Enforcement Administration |
| Government Initiative | Make America Healthy Again Commission |
| Lead Political Figure | Robert F. Kennedy Jr. |
| Key Health System (UK) | NHS England |
| Reference | https://www.nih.gov |
Every worry has been heightened by shortages. To stop diversion and abuse, the Drug Enforcement Administration in the United States enforces stringent production quotas on stimulant ingredients. Critics contend that those quotas have not increased in line with the number of new diagnoses.
A “perfect storm” has resulted, with patients left in a bind, supply limited, and demand rising. Drugs are rationed by pharmacies.
In the middle of a treatment, doctors change brands. Some patients discreetly confess to skipping weekends, halving their medication, or extending their dosages.
The issue appears somewhat different in the UK, but it seems equally pressing. Numerous drugs are in short supply as a result of global manufacturing problems and supply chain disruptions.
According to reports, NHS England spends more than £160 million a year on ADHD services, in part due to an increase in the cost of medications and a deluge of private assessments.
Patients in some areas have to wait literally years to be evaluated by specialists. One can’t help but wonder if the system is diagnosing more problems than it can responsibly handle as the backlog grows.
Politics, on the other hand, almost never refuses an opportunity. The Robert F. Kennedy Jr.-chaired Make America Healthy Again Commission in Washington has demanded a new investigation into what it refers to as children’s “overreliance” on medicine.
Clinicians have been uneasy about the language, especially the references to the “threat posed by” specific medications. Drug approvals cannot be directly revoked by executive orders, but the symbolism is important. Parents hear it. Physicians hear it. It’s definitely heard by investors.
Long-term safety concerns are also coming up again at the same time. Long-term, high-dose stimulant use may be linked to increased cardiovascular risks, such as hypertension and arterial disease, according to a sizable Swedish study published in 2024.
The results have introduced another level of complexity, but they do not establish causation. The long horizon is important for drugs that are frequently started in childhood and taken into adulthood. Whether the monitoring systems in place are reliable enough to track these risks over decades is still up in the air.
However, the argument is not at all biased. ADHD medication has also been associated in studies with lower risks of substance abuse, traffic accidents, and even criminal activity. Researchers in Sweden discovered quantifiable drops in criminal convictions and suicide attempts among those undergoing treatment.
Medication is often described by clinicians as leveling the playing field rather than as a shortcut. One pediatric neurologist recently employed an eye-opening metaphor: the child still runs the race even though the starting line is moved closer by medication.
At that point, the discussion starts to feel very human. Medication is initially resisted by many parents. They are concerned about personality changes, disturbed sleep, and appetite loss.
After a few months, they observe that their child is still making friends, finishing their homework, and sitting through dinner. Improvement can feel brittle and almost miraculous. Anxiety that verges on panic is sparked by the notion that access could tighten.
Another issue is overdiagnosis, a term that comes up frequently but is difficult to define. Adults sharing late-life diagnoses and accounts of years of silent struggle on social media have surely raised awareness. Platforms for telehealth, especially during the pandemic, facilitated and expedited assessments.
According to some experts, many women were neglected in the past and are only now getting the care they need. Some people believe that diagnostic thresholds might be slipping. Both might be accurate.
The larger picture makes things even more difficult. Approximately 5% of children and 3% of adults worldwide are thought to have ADHD, although medication use in some nations is still below those prevalence estimates.
That implies that some groups are receiving inadequate treatment, despite headlines being dominated by concerns about excessive treatment. Unmet need and rising demand are two conflicting realities that healthcare systems must deal with.
Not a rejection of ADHD medication is what is happening in the US and the UK. It’s a more subtle thing.
In an effort to stop abuse, regulators are strengthening oversight, requesting more long-term data, reviewing telehealth regulations, and more. Meanwhile, patients are negotiating political polarization and empty pharmacy shelves.
The argument seems less like a straightforward medical dispute and more like a reflection of larger cultural anxiety regarding productivity, mental health, childhood, and the place of drugs in contemporary society. At the core of that tension are stimulants, which increase focus while posing awkward queries.
It’s unclear where this will go. Production quotas are subject to change. Supply chains might level off. More safety research could either clarify or make things more complicated.
ADHD medication currently holds a unique position: it is widely used, beneficial to many, and under more scrutiny than it has ever been. Additionally, patients continue to wait in pharmacies on both sides of the Atlantic.